With further research of RIKEN's stem cells:
1. The recent monkey-to-monkey trials did not use their "allogeneic iPSC-retinal pigment epithelial cells". And they plan to use these allogeneic cells in their next trial.
2. Major concerns about potential immunogenecity (immune rejection) of their type of stem cells have been raised by their peers.
(http://stemcellassays.com/2015/09/first-ips-cell-clinical-trial-insights/)
Either way, RIKEN in their next clinical trial with the use of their "allogeneic stem cells" are also in a fight to prove whether their iPS cell bank are truly useful/valid or not.
http://www.riken.jp/en/pr/press/2016/20160916_2/
- Forums
- ASX - By Stock
- CYP
- riken temcell
riken temcell, page-24
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CYP (ASX) to my watchlist
|
|||||
Last
20.0¢ |
Change
-0.005(2.44%) |
Mkt cap ! $36.11M |
Open | High | Low | Value | Volume |
20.5¢ | 21.5¢ | 20.0¢ | $13.43K | 65.55K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 109917 | 20.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
25.0¢ | 9225 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 109917 | 0.200 |
2 | 68825 | 0.195 |
3 | 122713 | 0.190 |
3 | 65055 | 0.180 |
3 | 7139 | 0.175 |
Price($) | Vol. | No. |
---|---|---|
0.250 | 9225 | 2 |
0.255 | 187726 | 1 |
0.270 | 30000 | 1 |
0.280 | 8209 | 2 |
0.285 | 60000 | 1 |
Last trade - 16.10pm 15/08/2024 (20 minute delay) ? |
Featured News
CYP (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online